CTD Dossier Templates for the US and EU Regulatory Authorities
Accelerate Your Path to Market with Zenovel’s expert regulatory solutions and dossier templates USA-EU, from IND to MAA
We assist you in seamless & streamlined process of regulatory submission by our comprehensive CTD dossier templates services including dossier templates USA-EU
Most regulatory applications must be submitted in ICH-harmonized CTD format, as per EU and US Health Authority regulations. Efficient management of submissions and lifecycles is achieved through a thorough submission methodology and standardized CTD dossier templates, all within reasonable time and financial constraints.
We offers customized CTD dossier templates for various regulatory applications, including INDs, IMPDs, MAAs, BLAs, NDAs, and ANDAs for pharmaceutical and biological goods, making them easier to understand and utilize.
- Our Key Features of templates
We offer templates for the following application submissions
Investigational New Drug Application (IND) template
Our IND templates simplify the authoring and submission of Phase I, II, and III clinical trial applications to the US FDA. These templates provide detailed information on regulatory requirements for biological and pharmaceutical goods, allowing applicants to comply with FDA expectations. The metadata also provides in-depth information on potential clinical-hold problems related to Clinical Management Control (CMC) requirements and advice on handling CMC-related clinical-hold problems.
Biologic Dossier Template- Biologic Licensing Application (BLA)/ Marketing Authorization Application (MAA)/ New Drug Application
We have developed CTD templates for US and EU biologics marketing authorization dossier submissions. These templates are encrypted with specific metadata for each agency and application, providing guidance on regulatory requirements and potential issues like application-hold and refuse-to-file. The metadata also outlines standard specifications for biological products and production processes. The applicant can adhere to unique metadata for each application type and agency, and the same CTD data package can be updated or modified for the next country-submission.
Investigational Medicinal Product (IMP) Dossier Template
We has personalised templates simplify the creation and submission of an IMPD for clinical programmes to EU HAs and member states. These templates must satisfy pharmaceutical and biological product regulations, allowing applicants to adhere to metadata based on product type to meet HA needs and expectations.
New Drug Application (NDA)-505 (b)2 Template
Pharmaceutical product innovators can file for innovations in generic pharmaceuticals under the FDC Act by altering formulation, components, administration method, dosage schedule, and API using customised NDA 505(b) 2 templates. These templates provide regulatory references for most RTR concerns for all types of pharmaceutical products, including tablets, capsules, solutions, suspensions, injectable, and topical.
Abbreviated New Drug Application (ANDA) templates
Insufficient understanding of GDUFA II, RTR prerequisites, and ANDA readiness can lead to ANDA rejections, costing company’s time and money. To avoid this, company should submit an ANDA using the correct data presentation strategy, including in-depth details and regulatory references for various generic medicine dosage forms.
EU marketing Authorization (MAA) templates.
MAA CTD templates have been prepared for EU MAAs relating to pharmaceutical items, containing encrypted metadata outlining regulatory requirements for generic pharmaceutical goods in various formulation forms such as tablets, capsules, solutions, suspensions, and injectables, to be submitted via relevant processes.
- Why Choose Zenovel ?
- Complete Expertise
Ensure your submission meets highest standards by our deep understanding of the regulatory process- US and EU authorities.
- Tailored Solutions
- User Friendly Design
Our pre-formatted templates and checklists are easy to edit, allowing you to customize documents.
- Metadata Encryption
For product registration, each template is encrypted with specific metadata prepared by regulatory experts.
People Also Ask (FAQs)
A Common Technical Document (CTD) dossier template provides a standardized structure for preparing regulatory submissions for pharmaceutical products. It organizes data into five modules covering administrative information, summaries, quality documentation, nonclinical studies, and clinical study reports.
CTD dossier templates ensure consistency and compliance with international regulatory requirements. By following a structured format, companies can present data clearly and efficiently, helping regulatory authorities review applications more quickly and reducing the chances of submission errors. Zenovel supports this process by providing compliant, ready-to-use CTD templates along with expert guidance, ensuring accurate documentation and smoother regulatory submissions.
A CTD dossier consists of five modules: administrative information, summaries, quality documentation, non-clinical study reports, and clinical study reports. These modules collectively provide regulators with comprehensive information about the safety, quality, and efficacy of a pharmaceutical product.
Zenovel provides expert regulatory affairs support for preparing CTD and eCTD dossier templates aligned with the requirements of authorities such as the U.S. Food and Drug Administration and the European Medicines Agency. Their team assists with organizing documentation, ensuring correct module structuring, and preparing submission-ready templates that comply with international regulatory standards.
While the CTD format is harmonized globally under the ICH guidelines, there are still regional differences in Module 1, which contains administrative and regional information. Regulatory authorities such as the U.S. Food and Drug Administration and the European Medicines Agency require specific documents and formatting within this module, so companies must adapt their CTD templates accordingly when submitting in different regions.
Blogs and news
Our Latest Article
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of formulations and device technology, making bioequivalence more difficult to establish compared to conventional oral dosage forms. Examples include Albuterol MDIs (metered dose inhalers), DPIs Dry Powder Inhalers, and nebulized therapies,
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
